Gene Therapy For Rare Disease Market Size, Share Analysis, Growth Trends and Forecast 2026-2033

Gene Therapy for Rare Disease Market Overview

The gene therapy market for rare diseases is poised for continued growth, driven by ongoing technological innovations, expanding clinical applications, and increased investment. However, addressing the challenges related to cost, access, and regulatory complexities will be critical for realizing the full potential of gene therapies. Collaborative efforts between governments, pharmaceutical companies, and non-profits will be essential to ensure that gene therapies can be available to needy patients, especially in underserved regions.

Expansion into emerging markets is further accelerating the market growth. For instance, in May 2025, Sarepta Therapeutics, Inc. announced that the Japanese Ministry of Health, Labour, and Welfare (MHLW) approved ELEVIDYS (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy (DMD) under the conditional and time-limited approval pathway in Japan. ELEVIDYS is approved for individuals aged 3 to less than 8 years old, who do not have any deletions in exon 8 and/or exon 9 in the DMD gene, and who are negative for anti-AAVrh74 antibodies. This is the first global approval to include individuals younger than 4 years of age.

Executive Summary

For more details on this report – Request for Sample

Gene Therapy for Rare Disease Market Dynamics: Drivers & Restraints

Advancements in gene editing technologies are significantly driving the gene therapy for rare disease market growth

CRISPR-Cas9, a revolutionary gene-editing tool, allows scientists to make highly targeted alterations in the DNA sequence. This technology has unlocked new possibilities for treating rare diseases by directly correcting genetic mutations at their source, offering a more effective solution compared to traditional therapies. The approval of Exagamglogene autotemcel (Casgevy), a CRISPR-based gene therapy for Sickle Cell Disease (SCD), marks a significant milestone.

For instance, in January 2024, Vertex Pharmaceuticals Incorporated released that the Saudi Food and Drug Authority (SFDA) granted Marketing Authorization for CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). CASGEVY is approved for treating people 12 years of age and older with SCD or TDT. It demonstrates how CRISPR is used to provide a potentially curative solution for rare genetic conditions

Gene editing allows for more personalized approaches, such as delivering treatments to specific tissues or organs affected by rare diseases. This increases the therapy's effectiveness while minimizing unwanted side effects. For instance, for Inherited Retinal Diseases (IRD), gene editing tools are used to correct genetic mutations in retinal cells, potentially restoring vision. Luxturna is a prime example of gene therapy targeting inherited retinal conditions, and advancements in editing technologies could extend this to rarer diseases.

The high cost associated with gene therapies is hampering the gene therapy for rare disease market.

Gene therapies often involve complex manufacturing processes, such as the production of viral vectors (used to deliver the therapeutic genes), which require highly specialized facilities and technology. This makes the production process expensive. For instance, the gene therapies Zynteglo and Skysona are priced at US$ 2.8 million and US$ 3 million per dose. Moreover, Zolgensma has a reported list price of US$ 2.1 million. This price tag is due to the intricate manufacturing process, including the creation of the adeno-associated virus (AAV) vector used in the therapy.

The development of gene therapies involves lengthy and expensive clinical trials, especially when targeting rare diseases with small patient populations. These trials require extensive regulatory approvals, advanced scientific research, and personalized patient treatments. For instance, Luxturna, a gene therapy for Leber’s congenital amaurosis, took over 10 years from development to approval, and its cost is $850,000 per patient.

Gene Therapy for Rare Disease Market Segmentation Analysis

The global gene therapy for rare disease market is segmented based on approach, vector type, technique, application, and region.

Viral Vectors Segment Dominates the Market Owing to Proven Clinical Success and Expanding Regulatory Approvals

The Viral Vectors segment holds the largest share of the global Gene Therapy for Rare Disease Market, primarily due to its high transduction efficiency, long-term therapeutic gene expression, and established use across approved gene therapies for rare genetic disorders. Adeno-associated virus (AAV), lentiviral, and retroviral vectors continue to be the preferred delivery platforms for treating inherited diseases because of their ability to effectively target specific tissues and deliver durable therapeutic outcomes. Increasing regulatory approvals, expanding clinical pipelines, and continued investments in vector manufacturing technologies are further strengthening the segment's leadership position.

Reflecting this industry trend, in December 2024, Roche announced that the U.S. FDA approved Itovebi (inavolisib) for a specific breast cancer indication, while its gene therapy subsidiary Spark Therapeutics continued advancing its rare disease pipeline through ongoing research and development initiatives. Across the broader industry, leading companies are expanding viral vector manufacturing capacity and investing in next-generation delivery technologies to support the growing commercialization of rare disease gene therapies.

Gene Editing Segment Witnesses Rapid Growth Driven by Advances in Precision Genome Engineering

The Gene Editing segment is expected to register the fastest growth during the forecast period, driven by significant advances in CRISPR-based technologies, base editing, and prime editing for the treatment of rare inherited disorders. Unlike conventional gene addition approaches, gene editing enables precise correction of disease-causing mutations, offering the potential for durable or one-time treatments. Increasing research collaborations, growing clinical trial activity, and continuous innovation in genome engineering technologies are accelerating adoption across multiple rare disease indications.

Supporting this momentum, in April 2025, Vertex Pharmaceuticals and CRISPR Therapeutics continued expanding the commercialization of CASGEVY, the first approved CRISPR/Cas9 gene-edited therapy for eligible patients with sickle cell disease and transfusion-dependent beta-thalassemia. The milestone highlights the increasing clinical and commercial acceptance of precision gene-editing technologies and reinforces their growing role in the future of rare disease treatment.

Gene Therapy for Rare Disease Market Regional Analysis

North America is expected to dominate the global gene therapy for rare disease market with a 58.7% share in 2024 

North America, especially the US FDA, offers Orphan Drug Designation and fast-track approval processes for gene therapies targeting rare diseases. This regulatory support accelerates the development and commercialization of gene therapies in North America, making it a key region for the adoption of these treatments. The list of some gene therapies approved by the FDA includes:

Many leading biotech companies headquartered in North America are at the forefront of gene therapy development. These companies play a critical role in pushing forward research, clinical trials, and product commercialization, making North America the global leader in gene therapy advancements. For instance, Spark Therapeutics, based in the U.S., developed Luxturna, the first FDA-approved gene therapy for inherited retinal disease. This success story highlights North America's leadership in gene therapy innovation and treatment for rare diseases.

Gene Therapy for Rare Disease Market Top Companies

Top companies in the gene therapy for rare disease market include Alnylam Pharmaceuticals, Inc., Spark Therapeutics, Inc., Novartis AG, bluebird bio, Inc., Ferring Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics, Inc., CSL Behring LLC, Amgen, Inc., Orchard Therapeutics Group., Krystal Biotech, Inc., and others. 

Key Takeaways

• The gene therapy for rare disease market is experiencing strong momentum as advances in gene-editing technologies, viral vector engineering, and precision medicine continue to expand the availability of transformative treatment options for previously untreatable rare genetic disorders.
• North America maintains a leading position in the global market, supported by its advanced biotechnology ecosystem, favorable regulatory pathways for orphan drugs, strong presence of leading gene therapy developers, and increasing investments in rare disease research and commercialization.
• Europe represents a significant share of the market, driven by supportive orphan medicinal product regulations, expanding clinical trial activities, growing collaborations between academic institutions and biotechnology companies, and improved access to innovative genetic therapies.
• The rising prevalence of rare inherited genetic disorders, combined with improved genetic screening, next-generation sequencing, and earlier diagnosis, is accelerating demand for targeted gene therapies capable of addressing the underlying causes of disease.
• Growing regulatory support through orphan drug designations, accelerated approval pathways, and incentives for rare disease drug development is encouraging pharmaceutical and biotechnology companies to expand their gene therapy pipelines.
• Industry participants are increasingly prioritizing investments in scalable manufacturing technologies, advanced viral vector production, long-term clinical efficacy, and strategic collaborations to strengthen commercialization capabilities and improve patient access to innovative gene therapies.
• Increasing partnerships among biotechnology companies, research institutions, healthcare providers, and patient advocacy organizations are creating significant opportunities to accelerate clinical development, expand treatment availability, and improve outcomes for patients living with rare diseases.

Gene Therapy For Rare Disease Market Scope

Why Purchase This Report?

The Gene Therapy for Rare Disease Market report provides comprehensive intelligence for biotechnology companies, pharmaceutical manufacturers, investors, research organizations, healthcare providers, and policymakers seeking to understand the rapidly evolving landscape of rare disease gene therapies.

• Gain detailed insights into key market drivers, restraints, opportunities, and emerging therapeutic trends.
• Assess the impact of regulatory incentives, orphan drug policies, and accelerated approval pathways on market growth.
• Understand advancements in gene editing, viral vector technologies, and next-generation gene delivery platforms.
• Evaluate commercialization strategies, clinical pipeline developments, and demand across major rare disease indications.
• Benchmark leading biotechnology companies, strategic collaborations, licensing agreements, and competitive positioning.
• Identify high-growth opportunities across inherited genetic disorders, neuromuscular diseases, hematological disorders, metabolic disorders, and ophthalmic diseases.
• Support investment decisions, product development strategies, partnership planning, and long-term business expansion.

The global gene therapy for rare disease market report delivers a detailed analysis with 73 key tables, more than 63 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.

Target Audience

• Biotechnology and Pharmaceutical Manufacturers
• Healthcare Providers and Hospital Networks
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Biotechnology Companies
• Clinical Research Organizations (CROs)
• Strategic Consulting and Market Intelligence Organizations
• Academic and Research Institutions Focused on Gene Therapy, Genomics, and Rare Diseases

Suggestions for Related Reports

• Gene Therapy Market
• Cell and Gene Therapy Market
• Cell Therapy Market
• Rare Disease Therapeutics Market
• CRISPR Gene Editing Market